Inex receives CE-IVD mark for ovarian cancer rapid test
The point-of-care test can distinguish benign from malignant ovarian cysts in an operating theatre setting.

The point-of-care test can distinguish benign from malignant ovarian cysts in an operating theatre setting.
The study will enrol people with SCI suffering from orthostatic hypotension.
The CE marking will enable Lucira to sell and distribute the two tests throughout the EU.
The Netherlands Cancer Institute will co-develop personalised treatment management software solutions.
The researchers investigated whether HE4 could help identify ovarian cancer more precisely.
The Aidaptus auto-injector can accommodate 1ml and 2.25ml prefilled glass syringes in the same base device.
The test is expected to detect around 50 infants with retinoblastoma every year.
The ongoing war in Ukraine has created numerous logistical challenges that will impact the delivery of medical devices to Russia.
By